In a filing, Cidara Therapeutics Inc revealed its Chief Medical Officer Davarpanah Nicole Negar unloaded Company’s shares for reported $29797.0 on Sep 11 ’25. In the deal valued at $62.86 per share,474 shares were sold. As a result of this transaction, Davarpanah Nicole Negar now holds 31,418 shares worth roughly $2.84 million.
Then, RA CAPITAL MANAGEMENT, L.P. bought 2,272,727 shares, generating $99,999,988 in total proceeds. Upon buying the shares at $44.00, the Director now owns 3,365,523 shares.
Before that, Mineo Chrysa bought 2,270 shares. Cidara Therapeutics Inc shares valued at $49,281 were divested by the Director at a price of $21.71 per share. As a result of the transaction, Mineo Chrysa now holds 2,270 shares, worth roughly $0.21 million.
A number of analysts have revised their coverage, including Citizens JMP’s analysts, who began to cover the stock in mid March with a ‘”a Mkt outperform”‘ rating. RBC Capital Mkts started covering the stock on December 13, 2024. It rated CDTX as “an Outperform”.
Price Performance Review of CDTX
On Friday, Cidara Therapeutics Inc [NASDAQ:CDTX] saw its stock jump 6.77% to $90.5. Over the last five days, the stock has gained 31.71%. Cidara Therapeutics Inc shares have risen nearly 740.25% since the year began. Nevertheless, the stocks have risen 236.66% over the past one year. While a 52-week high of $90.64 was reached on 09/26/25, a 52-week low of $10.14 was recorded on 04/07/25.
Levels Of Support And Resistance For CDTX Stock
The 24-hour chart illustrates a support level at 85.44, which if violated will result in even more drops to 80.38. On the upside, there is a resistance level at 93.20. A further resistance level may holdings at 95.90.
How much short interest is there in Cidara Therapeutics Inc?
A steep rise in short interest was recorded in Cidara Therapeutics Inc stocks on 2025-09-15, growing by 0.11 million shares to a total of 2.19 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-15 was 2.08 million shares. There was a rise of 5.12%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 08, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $33 price target.
